| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
114,670,000 as of 6/30 |
| Market
Cap: |
231.63(M) |
| Last
Volume: |
512,057 |
Avg
Vol: |
909,824 |
| 52
Week Range: |
$1.22 - $2.69 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : 8.1 |
| Insider 6 Months : 8.1 |
| Insider 3/6 Months : 16.6 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
Company Profile Novavax is a clinical-stage biopharmaceutical company focused on developing recombinant vaccines to address a range of infectious diseases. Co.'s technology platform is based on proprietary recombinant vaccine technology that includes virus-like particles and recombinant nanoparticle vaccines. Co.'s product pipeline targets a range of infectious diseases and its vaccine candidates are in or have completed clinical trials that target pandemic influenza, seasonal influenza and respiratory syncytial virus. Further, CPL Biologics Private Limited, Co.'s joint venture company in India, is developing a rabies vaccine candidate.
|
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
100,000 |
100,000 |
100,000 |
612,000 |
| Total Buy Value |
$203,000 |
$203,000 |
$203,000 |
$922,200 |
| Total People Bought |
1 |
1 |
1 |
7 |
| Total Buy Transactions |
1 |
1 |
1 |
14 |
| Total Shares Sold |
79,000 |
79,000 |
79,000 |
1,461,752 |
| Total Sell Value |
$193,540 |
$193,540 |
$193,540 |
$1,893,386 |
| Total People Sold |
1 |
1 |
1 |
1 |
| Total Sell Transactions |
1 |
1 |
1 |
5 |
| End Date |
2013-02-24 |
2012-11-23 |
2012-05-25 |
2011-05-26 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Evans Gray C |
Director |
– • – |
2013-04-24 |
4 |
S |
$2.44 |
$193,540 |
D/D |
(79,000) |
702,558 |
|
17% |
|
| Young James F |
Director |
– • – |
2013-03-11 |
4 |
B |
$2.03 |
$203,000 |
D/D |
100,000 |
300,000 |
2.39 |
-1% |
|
| Hahn Timothy Jon |
SVP, Manufacturing & PD |
• – – |
2012-05-14 |
4 |
B |
$1.33 |
$39,900 |
D/D |
30,000 |
50,000 |
2.74 |
59% |
|
| Glenn Gregory M |
Chief Scientific Officer |
• – – |
2012-05-10 |
4 |
B |
$1.35 |
$33,750 |
D/D |
25,000 |
29,000 |
2.74 |
48% |
|
| Douglas Richard |
Director |
– • – |
2012-04-10 |
4 |
B |
$1.21 |
$60,500 |
D/D |
50,000 |
200,000 |
2.39 |
75% |
|
| Glenn Gregory M |
Chief Scientific Officer |
• – – |
2011-12-05 |
4 |
B |
$1.50 |
$3,000 |
D/D |
2,000 |
418,000 |
2.66 |
-16% |
|
| Wilson Russell P |
SVP, Business DevelopmentOffic |
• – – |
2011-12-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
50,000 |
|
-14% |
|
| Young James F |
Director |
– • – |
2011-12-01 |
4 |
B |
$1.46 |
$292,000 |
D/D |
200,000 |
440,000 |
2.39 |
-14% |
|
| Glenn Gregory M |
Chief Scientific Officer |
• – – |
2011-11-29 |
4 |
B |
$1.26 |
$2,520 |
D/D |
2,000 |
416,000 |
2.66 |
-2% |
|
| Hahn Timothy Jon |
SVP, Manufacturing & PDOfficer |
• – – |
2011-09-22 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
20,000 |
|
5% |
|
| Evans Gray C |
Director |
– • – |
2011-08-23 |
4/A |
S |
$1.22 |
$581,423 |
D/D |
(476,576) |
773,878 |
|
- |
|
| Evans Gray C |
Director |
– • – |
2011-08-22 |
4/A |
S |
$1.25 |
$268,500 |
D/D |
(214,800) |
1,250,454 |
|
- |
|
| Erck Stanley C |
President and CEO |
• • – |
2011-08-19 |
4 |
B |
$1.26 |
$16,380 |
D/D |
13,000 |
13,000 |
2.81 |
- |
|
| Erck Stanley C |
President and CEO |
• • – |
2011-08-10 |
4 |
B |
$1.24 |
$20,524 |
D/D |
16,552 |
16,552 |
2.81 |
2% |
|
| Erck Stanley C |
President and CEO |
• • – |
2011-08-09 |
4 |
B |
$1.24 |
$41,476 |
D/D |
33,448 |
33,448 |
2.81 |
-6% |
|
| Trizzino John |
Snr. VP, Int & Govt Alliances |
• – – |
2011-08-09 |
4 |
B |
$1.18 |
$23,800 |
D/D |
20,000 |
10,000 |
2.74 |
-6% |
|
| Driscoll Frederick W |
VP, CFO & Treasurer |
• – – |
2011-08-09 |
4 |
B |
$1.18 |
$23,600 |
D/D |
20,000 |
20,000 |
2.74 |
-6% |
|
| Douglas Richard |
Director |
– • – |
2011-08-09 |
4 |
B |
$1.20 |
$60,000 |
D/D |
50,000 |
50,000 |
2.39 |
-6% |
|
| Evans Gray C |
Director |
– • – |
2011-06-23 |
4 |
S |
$1.22 |
$581,423 |
D/D |
(476,576) |
773,878 |
|
27% |
|
| Evans Gray C |
Director |
– • – |
2011-06-22 |
4 |
S |
$1.25 |
$268,500 |
D/D |
(214,800) |
1,250,454 |
|
21% |
|
| Douglas Richard |
Director |
– • – |
2011-06-20 |
4 |
B |
$2.04 |
$101,750 |
D/D |
50,000 |
50,000 |
2.39 |
-14% |
|
| Glenn Gregory M |
Chief Scientific Officer |
• – – |
2011-04-07 |
4 |
S |
$2.56 |
$133,120 |
D/D |
(52,000) |
414,000 |
|
47% |
|
| Glenn Gregory M |
Chief Scientific Officer |
• – – |
2010-08-25 |
4 |
B |
$2.01 |
$4,018 |
D/D |
2,000 |
2,000 |
2.66 |
25% |
|
| Glenn Gregory M |
Chief Scientific OfficerOffice |
• – – |
2010-07-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
50,000 |
|
15% |
|
| Thornton Mark Owens |
SVP & Chief Medical OfficerOff |
• – – |
2010-05-24 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
25,000 |
|
-8% |
|
121 Records found
|
|
Page 1 of 5 |
|
|
0.02 (0.98%) 
